Cellontech's 'Katisil' Treatment Effect Adopted by International Journal... "Cartilage Regeneration Increased by 50%"

Cellontech, a subsidiary of SCN Engineering, has demonstrated the superior tissue regeneration capability of its new product for joint cartilage regeneration treatment, ‘Cartiseal’.

Cellontech, a bio company specializing in regenerative medicine, announced on the 18th that a clinical paper on the therapeutic efficacy of Cartiseal has been accepted by the SCIE (Science Citation Index Expanded) international journal TERM (Tissue Engineering and Regenerative Medicine).

Cartiseal is a porous sponge-type implantable tissue regeneration scaffold designed to promote joint cartilage formation, made from Cellontech’s proprietary bio-collagen. It aids the localization of chondrocytes and bone marrow cells during procedures such as improved microfracture surgery or autologous bone marrow stem cell therapy (BMAC), thereby inducing effective cartilage tissue regeneration.

To verify the cartilage regeneration treatment effect of Cartiseal used in microfracture surgery and autologous bone marrow stem cell therapy, Cellontech conducted animal tests divided into a test group (Cartiseal), a positive control group (Swiss company G’s ‘Chondroguide’), and a negative control group (no treatment). The evaluation was performed using macroscopic analysis and quantitative analysis by histological grading through histopathological examination, confirming Cartiseal’s superior regenerative treatment effect on cartilage defects.

According to histological evaluation scores, 12 weeks after autologous bone marrow stem cell therapy, the test group Cartiseal scored 7.24 points, showing about 50% better tissue regeneration capability compared to the positive control group’s 14.46 points. Twelve weeks after microfracture surgery, Cartiseal scored 11.14 points, approximately 35% better than the negative control group’s 17.26 points. A lower histological evaluation score indicates higher tissue regeneration capability.

A Cellontech representative stated, “The competitiveness of Cartiseal stems from its development based on bio-collagen with excellent biocompatibility and tissue regeneration capability, reflecting a cell-friendly porous structure. The acceptance of our paper in this international journal once again proves that Cartiseal has differentiated performance compared to existing products.”

They added, “We will continue to carry out strategic sales and marketing activities so that Cartiseal, which is competitive in all aspects including technology and price in the implantable tissue regeneration scaffold market that has relied on imported collagen raw materials, firmly establishes itself as a domestic alternative.”

This content was produced with the assistance of AI translation services.